<DOC>
	<DOCNO>NCT00036738</DOCNO>
	<brief_summary>This phase II trial study well fludarabine phosphate total-body irradiation follow donor peripheral blood stem cell transplant work treat patient acute lymphoblastic leukemia chronic myelogenous leukemia respond previous treatment imatinib mesylate , dasatinib , nilotinib . Giving low dos chemotherapy , fludarabine phosphate , total-body irradiation ( TBI ) donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving mycophenolate mofetil cyclosporine transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate Total-Body Irradiation Followed Donor Peripheral Blood Stem Cell Transplant Treating Patients With Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia That Has Responded Treatment With Imatinib Mesylate , Dasatinib , Nilotinib</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether rate leukemia relapse decrease patient chronic myelogenous leukemia blast crisis ( CML-BC ) Philadelphia chromosome positive acute lymphoblastic leukemia ( Ph+ ALL ) responsive imatinib mesylate ( either dasatinib nilotinib patient imatinib-resistant disease intolerant imatinib ) follow nonmyeloablative hematopoietic stem cell transplantation ( HSCT ) compare historical control give high-dose conventional allogeneic HSCT chemotherapy . II . To determine whether rate transplantation-related mortality ( TRM ) decrease patient CML-BC Ph+ ALL responsive imatinib mesylate ( dasatinib nilotinib ) follow nonmyeloablative HSCT compare historical control give high-dose conventional allogeneic HSCT chemotherapy . SECONDARY OBJECTIVES : I . To evaluate whether donor lymphocyte infusion ( DLI ) safely used patient mixed full donor chimerism preemptive therapy eliminate minimal residual disease . OUTLINE : INDUCTION THERAPY : Patients continue receive imatinib mesylate orally ( PO ) , dasatinib PO , nilotinib PO twice daily day -2 resume day 14 blood count recover peripheral blood stem cell ( PBSC ) transplantation . NONMYELOABLATIVE CONDITIONING : Patients receive fludarabine intravenously ( IV ) day -4 -2 ; undergo TBI day 0 . TRANSPLANTATION : Patients undergo allogeneic PBSC transplantation day 0 . GRAFT-VERSUS-HOST-DISEASE ( GVHD ) PROPHYLAXIS : Patients receive mycophenolate mofetil ( MMF ) PO every 12 hour day 0-27 ( related donor recipient ) every 8 hour day 0-96 taper day 40 ( unrelated donor recipient ) . Patients also receive cyclosporine IV PO every 12 hour day -3 56 , follow taper day 57-180 ( relate donor recipient ) day -3 100 , follow taper day 101-177 ( unrelated donor recipient ) . DONOR LYMPHOCYTE INFUSION : Patients persistent disease GVHD stop GVHD prophylaxis receive donor lymphocyte infusion IV 30 minute every 28 day 3 dos . Treatment continue absence disease progression unacceptable toxicity . Patients follow periodically 2 year annually thereafter 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients = &lt; 12 year age must approve Fred Hutchinson Cancer Research Center ( FHCRC ) principal investigator ( PI ) advance Patients history Ph+ ALL CMLBC , receive imatinib mesylate , ( either dasatinib nilotinib ) &lt; 15 % blast morphologic marrow evaluation ; patient detectable Ph+ ALL morphologic molecular assay ( complete remission ) accept An appropriately human leukocyte antigen ( HLA ) match related unrelated donor must prospectively identify available donate filgrastim ( GCSF ) mobilize stem cell RELATED DONOR : Related donor HLA genotypically identical least one haplotype may genotypically phenotypically identical allele level HLAA , B , C , DRB1 , DQB1 ; Donor must consent GCSR administration leukapheresis ; Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) HLAMATCHED UNRELATED DONOR : FHCRC match allow grade 1.0 2.1 ; unrelated donor prospectively match HLAA , B , C , DRB1 DQB1 high resolution typing ; single allele disparity allow HLAA , B , C define high resolution type A positive antidonor cytotoxic crossmatch absolute donor exclusion ; donor exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow Only GCSF mobilize PBSC permit HSC source protocol Central nervous system ( CNS ) involvement leukemia refractory intrathecal chemotherapy ; prior HSCT ( patient must receive diagnostic lumbar puncture ( LP ) intrathecal ( IT ) chemotherapy per standard practice ) Fertile men woman unwilling use contraceptive technique 12 month follow treatment Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) ; exclusion apply patient nonhematologic malignancy require therapy Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence ; exclusion apply patient nonhematologic malignancy require therapy Females pregnant breastfeeding Patients human immunodeficiency virus ( HIV ) positive Patients poorly control hypertension despite multiple antihypertensive Adults : Karnofsky score &lt; 60 Pediatrics : Lansky playperformance score &lt; 40 Patients cardiac ejection fraction &lt; 35 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; ejection fraction require age &gt; 50 year history anthracycline exposure history cardiac disease ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 30 % Total lung capacity ( TLC ) &lt; 30 % Forced expiratory volume one second ( FEV1 ) &lt; 30 % and/or receive supplementary continuous oxygen ; FHCRC PI study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Creatinine level 2.2 X 's upper limit normal ( ULN ) laboratory analysis perform Patients active bacterial fungal infection unresponsive medical therapy For patient receive dasatinib nilotinib , baseline correct QT interval ( QTc ) ( Fridericia 's method ) prolongation great 500 msec RELATED DONORS : Identical twin Infection HIV Inability achieve adequate venous access Known allergy GCSF Current serious system illness Bone marrow ( BM ) donor HLAMATCHED UNRELATED DONORS : BM donor Donors HIVpositive and/or , medical condition would result increase risk GCSF mobilization harvest PBSC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>